Wohl & Fruchter LLP is investigating the fairness of Cross Country Healthcare's proposed sale to private equity firm Knox Lane at $13.25 per share, which is below its 52-week high and a previously agreed $18.61 per share offer from Aya Healthcare that was terminated. The law firm questions whether the CCRN board acted in shareholders' best interests and fully disclosed all material information. CCRN shareholders with concerns are encouraged to contact the firm for legal advice at no charge. This investigation highlights potential shareholder disputes over the sale price and transparency of the transaction.
Stifel Nicolaus increased its price target for Donaldson Company to $95, reflecting a 3.77% potential upside. Donaldson reported record fiscal 2026 results with $3.9 billion in sales, a 5% increase, and adjusted EPS up 8% to $3.98. The company also a...
Chagee Holdings Limited reported a 2.5% year-over-year revenue increase to approximately $503.3 million in Q2 2026, alongside a significant recovery in GAAP net income to RMB464.8 million. Despite a 9% decline in Greater China sales due to economic c...
Datadog CEO Olivier Pomel sold 47,054 shares of the company's stock, totaling $11.1 million. This significant sale could indicate personal financial planning or portfolio rebalancing. Investors may watch for any further insider transactions or compan...
In June 2026, President Donald Trump's investment team purchased up to $5 million worth of shares in three high-performing stocks, according to his latest financial disclosure. This move highlights the team's confidence in these companies amid a dyna...
Boliden AB plans to acquire Nexa Resources S.A. for $1.3 billion, boosting Nexa's stock target to $15.00 by Scotiabank, signaling a 10.38% potential gain. However, the deal is under legal scrutiny by Halper Sadeh LLC, which is investigating whether N...
